Format

Send to

Choose Destination
Anticancer Res. 2012 Jul;32(7):2471-8.

Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders.

Author information

1
MedInsight Research Institute, Telz Stone, Israel. moshe@medinsight.org

Abstract

Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; RizabenĀ®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This review summarizes recent evidence concerning the effect of tranilast on different tumor types and discusses the drug's possible mode of action in this area. In vivo and in vitro studies are covered, as well as evidence from clinical trials, in which tranilast was evaluated in various models of proliferative disorders. The findings presented in this report, demonstrate the excellent potential of tranilast in the management of certain types of tumor, and provide a strong rationale for the initiation of controlled clinical trials in this area.

PMID:
22753703
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center